Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy. (CPI)

June 4, 2026 updated by: Centre Antoine Lacassagne
This is a single-center pharmacokinetic study evaluating the impact of residual pembrolizumab levels on the efficacy of salvage chemotherapy following immunotherapy in patients with non-small cell lung cancer (NSCLC) or recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) not amenable to curative local treatment.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

110

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

- Patients over 18 years of age

- Patients diagnosed with :

  1. Non-small cell lung cancer (NSCLC), including adenocarcinoma and squamous cell carcinoma.

  2. Head and neck squamous cell carcinoma, p16-negative for oropharyngeal tumors.

    • Recurrent and/or metastatic tumor not amenable to curative locoregional treatment.

    • Disease progression under Pembrolizumab immunotherapy, administered at the standard dose of 200 mg every 3 weeks, as first-line treatment for metastatic disease, regardless of the number of cycles received, either as monotherapy or in combination with chemotherapy, as defined below:

      • For pulmonary adenocarcinomas: i. First-line treatment with Pembrolizumab in combination with a platinum agent (Carboplatin or Cisplatin) and Pemetrexed

    ii. Maintenance therapy with Pembrolizumab, with or without Pemetrexed.

    • For pulmonary squamous cell carcinomas: i. First-line treatment with Pembrolizumab in combination with a platinum agent (Carboplatin) and Paclitaxel

    +/- ii. Maintenance therapy with Pembrolizumab alone.

    • For head and neck squamous cell carcinomas : i. First-line treatment with Pembrolizumab in combination with a platinum agent (Carboplatin or Cisplatin) ± 5-Fluorouracil (5-FU) or Paclitaxel

    +/- ii. Maintenance therapy with Pembrolizumab alone.

    • Eligibility for salvage chemotherapy within standard care:

      • For pulmonary adenocarcinomas: weekly Paclitaxel, with or without Bevacizumab.

      • For pulmonary squamous cell carcinomas: Gemcitabine monotherapy.
      • For head and neck squamous cell carcinomas: weekly Paclitaxel and/or Cetuximab. Standard salvage chemotherapy may be initiated between Day 18 and Day 35 following the last Pembrolizumab injection, at standard doses.
    • Measurable disease according to RECIST 1.1 criteria.
    • Performance status (PS) 0 to 2.
    • Baseline laboratory results meeting the usual criteria permitting initiation of salvage chemotherapy.
    • Patients who has voluntarily agreed to participate in the study (including additional blood sampling) and has signed the informed consent form.

    • For the subpopulation with accessible tissue biopsy:

      • Patient agrees to undergo biopsy,
      • INR < 1.5, Platelets > 50000/μL.
    • Patients covered by a social security health insurance scheme.

    Exclusion Criteria:

    • History of cancer, except for cancers in complete remission for more than 3 years, fully resected cutaneous basal cell carcinomas, or treated carcinoma in situ or cervical intraepithelial neoplasia (in situ cervical epithelioma),
    • Patients participating in another clinical trial for which an exclusion period is specified,
    • Minor patients,

    • For the subpopulation with accessible tissue biopsy, patients receiving:

      • Clopidogrel (hydrogen sulfate) or Prasugrel (hydrochloride) or Ticlopidine (hydrochloride) without the possibility of discontinuation for 5 days,

      • Low-molecular-weight heparin (LMWH) without the possibility of dose suspension prior to the procedure,

      • Or Fondaparinux without the possibility of discontinuation,

      • Or Abciximab without the possibility of discontinuation for 24 hours and aPTT < 50s and ACT < 150s,

      • Or Eptifibatide or Tirofiban hydrochloride monohydrate or Argatroban without the possibility of discontinuation 4 hours before the procedure,

      • Or Bivalirudin without the possibility of discontinuation 2-3 hours before the procedure if CrCL > 50 mL/min, or 3-5 hours if CrCL < 50 mL/min,
      • Or Dabigatran etexilate without the possibility of discontinuation 2-3 days before the procedure if CrCL > 50 mL/min, or 3-5 days if CrCL < 50 mL/min.

    • Vulnerable persons as defined in Articles L1121-5 to L1121-8 :

      • Pregnant women, women in labour, and breastfeeding mothers,

      • Persons deprived of liberty by judicial or administrative decision, and persons hospitalized without consent under Articles L3212-1 and L3213-1 who do not fall under the provisions of Article L1121-8,
      • Persons admitted to a health or social care institution for purposes other than research,
      • Adults under legal protection measures or unable to express their consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Residual Pembrolizumab Exposure Assessment
Biological: Blood sampling
Patients will be followed according to standard clinical care. Biological samples collected include: (1) pharmacokinetic and extracellular vesicle analyses: 10 mL blood samples in EDTA tubes at 21±3, 35±3, 49±3, and 63±3 days after the last pembrolizumab administration (P1-P4); (2) pharmacogenetic analysis: one baseline 5 mL EDTA blood sample; (3) cytokine and immune cell analyses: at P1 and P4, collection of 2×4 mL lithium heparin tubes, 1×10 mL EDTA tube, and 1×5 mL dry tube.
Procedure: Tumor biopsies for biobank establishment (optional)

Depending on feasibility of the procedure, and at the discretion of the investigator, two biopsies will be performed in 20 consenting patients:

  • Biopsy B1: between the last administration of pembrolizumab (Day 0) and before initiation of standard salvage chemotherapy,
  • Biopsy B2: after initiation of salvage chemotherapy, at Day 63 ± 7 days after the last administration of pembrolizumab. If chemotherapy is discontinued prematurely, Biopsy B2 may only be performed if the patient has received at least 3 weeks of chemotherapy exposure.

Due to logistical constraints, these biopsies will be proposed to patients followed at CAL. They will be performed primarily in the interventional radiology department of CAL.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective response rate (ORR) at 3 months after initiation of salvage chemotherapy (RECIST v1.1)
Time Frame: 3 months after initiation of salvage chemotherapy

Objective response rate (ORR) includes the proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST version 1.1 criteria.

Tumor response will be assessed using routine imaging performed during standard clinical follow-up care.

ORR will be analyzed in relation to residual pembrolizumab (anti-PD-1) serum concentration measured 21 days after the last administration of pembrolizumab (P1), immediately prior to initiation of salvage chemotherapy.
3 months after initiation of salvage chemotherapy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Antoine Lacassagne

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2028

Study Registration Dates

First Submitted

May 29, 2026

First Submitted That Met QC Criteria

June 4, 2026

First Posted (Actual)

June 8, 2026

Study Record Updates

Last Update Posted (Actual)

June 8, 2026

Last Update Submitted That Met QC Criteria

June 4, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023/60
  • 2026-526866-26-00 (Ctis)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metastatic Head and Neck Squamous Cell Carcinoma

Clinical Trials on Blood sampling

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe